The Mirena IUD perforation injury class action stems from thousands of cases where Bayer’s hormone-releasing intrauterine device caused uterine perforations during or after insertion. In April 2018, Bayer settled approximately 4,800 uterine perforation and migration cases for $12.2 million, with individual payouts ranging from $2,500 to $50,000 depending on the severity of the injury and whether surgery was required for removal. A woman who had the Mirena inserted six weeks after childbirth, for example, faced a significantly higher risk of perforation—a risk the company did not adequately warn about—and required emergency surgery to repair the damage to her uterus. However, the landscape for Mirena perforation litigation has shifted dramatically since that settlement.
As of 2024, few to no personal injury lawyers are actively accepting new Mirena perforation and migration cases, and settlement prospects for any remaining claims are considered bleak. This dramatic shift reflects the closure of major litigation channels and the difficulty of proving damages in an increasingly saturated market where the deadline for many claims has passed. The Mirena continues to be marketed for contraception and management of heavy menstrual bleeding, but it carries documented perforation risks that have sparked decades of legal action. Understanding what happened in the perforation lawsuits, who was affected, and what compensation was actually paid can help consumers decide whether to seek legal representation for their own claims or understand the limitations they may face.
Table of Contents
- What Is Mirena IUD Perforation and Why Did It Become a Legal Issue?
- The 2018 Settlement: Who Got Paid and How Much?
- How Common Was Perforation, and Who Was Most at Risk?
- Why Are New Cases So Difficult to Pursue in 2024?
- The Shift to Breast Cancer Risk Litigation
- Medical and Surgical Consequences of Mirena Perforation
- Current Status and Future Outlook for Mirena Injuries
What Is Mirena IUD Perforation and Why Did It Become a Legal Issue?
Mirena IUD perforation occurs when the T-shaped plastic device perforates the wall of the uterus during insertion or in the days and weeks following the procedure. Once perforated, the IUD can migrate into the abdominal cavity, fallopian tubes, or bowel, where it may cause ongoing pain, infection, organ damage, or dangerous complications. In many cases, removal requires laparoscopic or open abdominal surgery. A perforated Mirena may not be immediately discovered—a woman might experience cramping, pain, or bleeding for months before imaging reveals the IUD has migrated outside the uterus.
The legal issue emerged because Bayer’s clinical trials reported perforation rates of less than 0.1%, yet postmarketing data collected by the FDA revealed much higher real-world rates: 6.3 perforations per 1,000 insertions for lactating women and 1.0 per 1,000 for non-lactating women. The company faced accusations that it minimized perforation risks in marketing materials and provider training, failed to adequately warn about the dramatically elevated risk when insertion occurred within six weeks of childbirth, and did not transparently communicate how common perforations truly were among certain populations. Over 8,000 serious adverse event reports were submitted to the FDA through June 2017 related to the Mirena, including hundreds of uterine perforation cases. This volume of reports, combined with the gap between disclosed trial rates and actual insertion-related injuries, fueled class action litigation in multiple states and federal court.
The 2018 Settlement: Who Got Paid and How Much?
Bayer’s $12.2 million settlement in April 2018 covered approximately 4,800 claimants with documented uterine perforation or migration injuries. The settlement amounts varied significantly based on the injury category: claims involving simple perforation with no surgery might receive $2,500, while claims involving emergency surgery, organ damage, or long-term complications could reach $50,000 or more. A woman who required emergency laparoscopic surgery to remove a perforated Mirena and then experienced ongoing adhesions and chronic pelvic pain would likely fall into a higher compensation tier than someone whose perforation was discovered incidentally on imaging and required only outpatient removal. One major limitation of this settlement was its finality.
Once the settlement fund was exhausted and claims were resolved, Bayer effectively closed the door on new litigation regarding perforation and migration. The company did not admit wrongdoing and no changes were made to how the product was marketed or inserted in clinical practice, though the FDA label was eventually updated to include postmarketing perforation data. Additionally, settling a claim required claimants to prove causation and injury documentation through medical records, which meant anyone without comprehensive medical records from the time of insertion and diagnosis faced significant barriers to compensation. Many women had to hire attorneys and provide extensive documentation just to receive a fraction of what they claimed was owed.
How Common Was Perforation, and Who Was Most at Risk?
Perforation risk was not uniform across all women using the Mirena. The FDA data showed that lactating women—those breastfeeding at the time of insertion—had a perforation rate of 6.3 per 1,000 insertions, more than six times higher than the 1.0 per 1,000 rate in non-lactating women. This disparity occurred because lactating women often had recently given birth, and their uteri were still soft and more prone to perforation. Insertion within six weeks of childbirth carried the highest perforation risk of all.
A woman who had the Mirena inserted four weeks after vaginal delivery, particularly while breastfeeding, was at substantial risk for perforation. If she experienced pain, abnormal bleeding, or feeling of the IUD strings disappearing, and her doctor failed to investigate quickly, the delayed diagnosis could allow the IUD to migrate further and cause additional internal damage. Bayer’s failure to clearly communicate this timing-dependent risk to both healthcare providers and patients was central to the legal complaints. The clinical trial data that reported less than 0.1% perforation excluded women within six weeks postpartum—a critical exclusion that made the trial appear much safer than real-world use. Once the Mirena became widely used for postpartum contraception, particularly among breastfeeding women, the perforation injuries mounted and eventually exceeded what the marketing materials had suggested was possible.
Why Are New Cases So Difficult to Pursue in 2024?
The closure of major settlement channels has made new Mirena perforation cases nearly impossible to litigate. Once Bayer’s $12.2 million settlement fund was distributed, the company was no longer facing coordinated class action pressure. Statutes of limitation—the legal deadlines for filing suit—have now expired in many states for injuries that occurred more than a decade ago. A woman injured by Mirena perforation in 2010 cannot file a lawsuit today in most jurisdictions, even if she discovered the injury only recently. Another barrier is the availability of legal representation.
Because the major settlement has already been paid and no new class action has been certified, most personal injury firms have shifted resources away from Mirena perforation claims. A woman seeking representation today would likely find that firms are unwilling to take on the cost and risk of pursuing an individual case that lacks the use of class certification. Unlike the organized settlements of years past, today’s potential claims would require an attorney to essentially litigate against a well-resourced corporation with no guarantee of success. For anyone with an older Mirena perforation claim that may have expired, pursuing recovery is now legally and practically impossible. This is a cautionary tale about the window of opportunity in pharmaceutical litigation: once a settlement closes and litigation momentum dissipates, injured consumers can be left without recourse.
The Shift to Breast Cancer Risk Litigation
While Mirena perforation litigation has effectively ended, Bayer now faces new allegations in federal court. In May 2024, a new class action lawsuit was filed in the Northern District of California alleging that Bayer failed to adequately warn users about the risk of breast cancer associated with the Mirena. Studies cited in the litigation show a 20 to 30 percent excess risk of breast cancer among Mirena users compared to non-users of hormonal contraceptives. This breast cancer litigation represents a different injury category and different legal timeline than the perforation cases of the past.
A woman diagnosed with breast cancer while using the Mirena, or within a few years of removal, may potentially have a claim under this newer lawsuit, depending on when her injury occurred and whether she can establish the connection to the device. However, proving causation in cancer cases is inherently more complex than proving a mechanical perforation from an insertion procedure. The emergence of breast cancer claims also highlights how pharmaceutical litigation evolves: once one major issue is settled, new safety data or research may spawn entirely different waves of litigation. For Mirena users, this means the legal issues are not fully behind the product, but the perforation-specific claims from prior decades are largely closed.
Medical and Surgical Consequences of Mirena Perforation
Uterine perforation from the Mirena can result in complications ranging from mild to life-threatening. Some women experience no symptoms and the perforation is discovered only when the IUD cannot be removed during a follow-up appointment or when imaging is done for an unrelated reason. Other women develop acute pain, severe cramping, and vaginal bleeding within hours or days of insertion—warning signs that demand immediate medical attention. When a perforated Mirena migrates into the abdominal cavity, it can become embedded in bowel tissue, cause adhesions that require extensive surgical adhesiolysis, or perforate the bowel itself, leading to sepsis and potential life-threatening infection.
A woman who had emergency bowel resection due to Mirena perforation faces long-term complications including altered bowel function and chronic pain. Surgical removal of a deeply embedded Mirena may require general anesthesia and a hospital stay, with recovery taking weeks. The $2,500 to $50,000 settlement range often did not fully compensate women for these surgical costs, ongoing pain management, lost wages, and psychological trauma. Many claimants felt the compensation was insufficient given the extent of their injuries, but the settlement was their only option to recover anything at all.
Current Status and Future Outlook for Mirena Injuries
As of 2024, the Mirena remains on the market and continues to be prescribed for both contraception and treatment of heavy menstrual bleeding. The product carries an updated FDA label that includes postmarketing perforation data, but Bayer has not withdrawn the device or implemented mandatory changes to insertion training. New legal action is focused on the breast cancer risk rather than perforation, suggesting that the mechanical injury chapter of Mirena litigation is largely closed.
For consumers considering the Mirena or dealing with past injuries, the key takeaway is that the window for perforation-related litigation has effectively closed. Anyone injured by Mirena perforation before the statute of limitations expired in their state should have sought legal representation years ago. The focus has shifted to newer claims, leaving those with older perforation injuries without recourse. This underscores the importance of understanding medical device risks at the time of insertion and seeking legal counsel promptly if complications arise.
You Might Also Like
- Zimmer Biomet Knee Replacement Defect Class Action
- Westlake Services Payment Fee Class Action Settlement
- Uber $8.4 Million Driver Background Check Class Action Settlement
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: